• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by PROCEPT BioRobotics Corporation

    2/26/26 4:51:15 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care
    Get the next $PRCT alert in real time by email
    S-8 1 proceptbiorobotics-2026sx8.htm S-8 Document

    As filed with the Securities and Exchange Commission on February 26, 2026
    Registration No. 333-   

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933
     
    PROCEPT BioRobotics Corporation
    (Exact name of Registrant as specified in its charter)
     
    Delaware 26-0199180
    (State or other jurisdiction of
    incorporation or organization)
     
    (I.R.S. Employer
    Identification Number)
    150 Baytech Drive, San Jose, California
     
    95134
    (Address of Principal Executive Offices) (Zip Code)
    2021 Equity Incentive Award Plan
    2021 Employee Stock Purchase Plan
    (Full Title of the Plan)
    Larry Wood
    Chief Executive Officer
    150 Baytech Drive
    San Jose, California 95134
    (650) 232-7200
    (Name, address, including zip code, and telephone number, including area code, of agent for service)
    Copies to:
    Alaleh Nouri
    Chief Legal Officer
    Jonathan Stone
    Deputy General Counsel
    150 Baytech Drive
    San Jose, California 95134
    (650) 232-7200
    B. Shayne Kennedy
    Drew Capurro
    Latham & Watkins LLP
    650 Town Center Drive, 20th Floor
    Costa Mesa, California 92626
    (714) 540-1235
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
    Large accelerated filer☒Accelerated filer☐
    Non-accelerated filer☐Smaller reporting company
    ☐
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐





    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission for the purpose of registering an additional 3,379,363 shares of common stock, par value $0.00001 per share, of PROCEPT BioRobotics Corporation (the “Registrant”), issuable under the following employee benefit plans for which registration statements on Form S-8 (File Nos. 333-259586, 333-264758, 333-270113, 333-277461 and 333-285387) are effective: (i) the 2021 Equity Incentive Award Plan which, as a result of an automatic annual increase provision therein, added 2,816,136 shares of common stock, and (ii) the Amended and Restated 2021 Employee Stock Purchase Plan which, as a result of the operation of an annual increase provision therein, added 563,227 shares of common stock.
    Pursuant to General Instruction E to Form S-8, the contents of the above-referenced prior registration statements are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

    Item 8. Exhibits.
    Exhibit
    Number
    Exhibit DescriptionForm
    Incorporated by Reference Date
    Number
    Filed
    Herewith
    4.1
    Amended and Restated Certificate of Incorporation
    8-K
    09/21/21
    3.1
    4.2
    Amended and Restated Bylaws
    8-K
    09/21/21
    3.2
    5.1
    Opinion of Latham & Watkins LLP
    X
    23.1
    Consent of Latham & Watkins LLP (included in Exhibit 5.1)
    X
    23.2
    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm
    X
    24.1
    Power of Attorney (included on signature page)
    X
    99.1
    2021 Equity Incentive Award Plan
    S-1/A09/08/2110.11
    99.1(a)
    Form of Option Agreement under the 2021 Equity Incentive Award Plan
    S-1/A09/08/21
    10.11(a)
    99.1(b)
    Form of RSU Agreement under the 2021 Equity Incentive Award Plan
    S-1/A09/08/2110.11(b)
    99.1(c)
    Form of PSU Agreement under the 2021 Equity Incentive Award Plan
    10-Q
    05/02/25
    10.1
    99.2
    Amended and Restated 2021 Employee Stock Purchase Plan
    10-Q
    10/28/24
    10.1
    107
    Fee Filing Table
    X



    SIGNATURES
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Jose, State of California, on this 26th day of February, 2026.
    PROCEPT BioRobotics Corporation
    By:
    /s/ Larry Wood
    Larry Wood
    Chief Executive Officer
    POWER OF ATTORNEY
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Larry Wood and Kevin Waters, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.



    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.
    SignatureTitleDate
    /s/ Larry Wood
    President, Director and Chief Executive Officer
    February 26, 2026
    Larry Wood
    (Principal Executive Officer)
    /s/ Kevin Waters
    EVP, Chief Financial Officer
    February 26, 2026
    Kevin Waters(Principal Financial and Accounting Officer)
    /s/ Thomas M. Prescott
    Director and Chair of the Board
    February 26, 2026
    Thomas M. Prescott
    /s/ Antal DesaiDirector
    February 26, 2026
    Antal Desai
    /s/ Amy DodrillDirector
    February 26, 2026
    Amy Dodrill
    /s/ Mary Garrett
    Director
    February 26, 2026
    Mary Garrett
    /s/ Taylor HarrisDirector
    February 26, 2026
    Taylor Harris
    /s/ Elisabeth Little
    Director
    February 26, 2026
    Elisabeth Little
    /s/ Frederic Moll, M.D.
    Director
    February 26, 2026
    Frederic Moll, M.D.

    Get the next $PRCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRCT

    DatePrice TargetRatingAnalyst
    2/26/2026Outperform → Perform
    Oppenheimer
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    12/12/2025$62.00Buy
    UBS
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    7/9/2025$70.00Overweight
    Stephens
    7/7/2025Perform
    Oppenheimer
    12/2/2024$105.00Overweight
    Morgan Stanley
    More analyst ratings

    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

    Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goa

    2/26/26 7:55:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day

    SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it has r

    2/23/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    SEC Filings

    View All

    SEC Form S-8 filed by PROCEPT BioRobotics Corporation

    S-8 - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 4:51:15 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by PROCEPT BioRobotics Corporation

    10-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 4:04:58 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 7:57:35 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by BofA Securities with a new price target

    BofA Securities downgraded PROCEPT BioRobotics from Neutral to Underperform and set a new price target of $20.00

    2/26/26 7:11:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    UBS initiated coverage on PROCEPT BioRobotics with a new price target

    UBS initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $62.00

    12/12/25 8:54:55 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO, CORP. SEC. Nouri Alaleh was granted 4,872 shares, increasing direct ownership by 7% to 77,345 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    2/25/26 4:47:31 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    EVP, CFO Waters Kevin was granted 3,532 shares, increasing direct ownership by 3% to 111,523 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    2/25/26 4:46:51 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    President, CEO Wood Larry L was granted 182,392 shares, increasing direct ownership by 5,694% to 185,595 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    9/4/25 5:39:56 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/12/24 5:01:10 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/4/24 1:31:19 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $PRCT
    Leadership Updates

    Live Leadership Updates

    View All

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Home Furnishings

    Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

    Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the

    8/15/24 10:00:00 AM ET
    $ISRG
    $PRCT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

    Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit

    4/2/24 8:00:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $PRCT
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day

    SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it has r

    2/23/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City

    SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, February 24, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it will host an in-person investor day event on Wednesday, February 25, 2026, at the NASDAQ Headquarters in New York City beginning at 8:00am Eastern Time. Guests are encouraged to register in advance by clic

    1/26/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care